Related Experiment Video
Updated: Mar 28, 2026

Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production
Published on: October 26, 2018
New England Compounding Center Indictment
Abstract:
This article is a review of the lapses in compliance with United States Pharmacopeia standards and pharmacy law as alleged by the New England Compounding Center indictment. This indictment was a result of an outbreak of fungal meningitis traced to fungal contamination of compounded methylprednisolone suspension for epidural steroid injections. This article is also intended as a gap analysis for compounders to review compliance at their own facility, and, if necessary, take the appropriate steps to implement best practices.
Insights
This review examines lapses in United States Pharmacopeia (USP) standards and pharmacy law compliance, highlighted by the New England Compounding Center indictment. It serves as a guide for compounding pharmacies to assess and improve their practices.
Area of Science:
- Pharmaceutical Compounding
- Pharmacy Law and Regulation
- Infection Control
Background:
- The New England Compounding Center indictment stemmed from a fungal meningitis outbreak.
- The outbreak was linked to contaminated compounded methylprednisolone for epidural injections.
- This highlights critical failures in sterile compounding practices.
Purpose of the Study:
- To review lapses in United States Pharmacopeia (USP) standards and pharmacy law compliance.
- To analyze the specific failures leading to the New England Compounding Center indictment.
- To provide a gap analysis tool for compounding facilities.
Main Methods:
- Review of the New England Compounding Center indictment details.
- Analysis of alleged violations of USP standards and pharmacy law.
- Comparative assessment framework for compounding compliance.
Main Results:
- Identified significant deviations from USP <797> and <71> standards.
- Highlighted failures in aseptic technique, environmental monitoring, and personnel training.
- Demonstrated a direct link between non-compliance and patient harm.
Conclusions:
- Compounding pharmacies must rigorously adhere to USP standards and pharmacy law.
- Implementing robust quality management systems is essential for patient safety.
- Continuous evaluation and improvement of compounding practices are necessary to prevent future outbreaks.
Related Concept Videos
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Production of Pharmaceuticals
Drug Regulation
Insensitive Nuclei Enhanced by Polarization Transfer (INEPT)
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
EDTA: Auxiliary Complexing Reagents
![Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F55537.jpg&w=3840&q=50)
